Moderna (MRNA) Revenue — Quarter Ended Mar 31, 2024
Revenue declined sharply in the current quarter compared to both the prior quarter and the same quarter a year earlier. The decrease reflects a continuation of the downward trend observed over recent periods.
Key takeaway
Quarter ended Mar 31, 2024 · FY2024 Q1
Revenue declined sharply in the current quarter compared to both the prior quarter and the same quarter a year earlier. The decrease reflects a continuation of the downward trend observed over recent periods.
Financial snapshot
Reported revenue, sequential change, year-over-year change, and trailing four-quarter revenue.
Quarter revenue
$167M
Revenue reported for this quarter.
Quarter-over-quarter
-94.1%
Change from the immediately preceding quarter.
Year-over-year
-91.0%
Change from the comparable year-ago quarter.
Trailing four quarters
$5.2B
Sum of the latest four reported quarters.
Quarterly revenue trend
The latest four reported quarters with year-over-year comparisons.
| Period ended | Revenue | Year-over-year change |
|---|---|---|
| Jun 30, 2023 | $344M | -92.8% |
| Sep 30, 2023 | $1.8B | -45.6% |
| Dec 31, 2023 | $2.8B | -44.7% |
| Mar 31, 2024 | $167M | -91.0% |
Revenue performance
The reported revenue for the quarter was lower than the preceding quarter, marking a further contraction from the level seen in the prior period.
Quarterly comparison
Compared to the same quarter one year earlier, revenue was also significantly lower. The sequential decline from the immediately preceding quarter was substantial, consistent with the overall downward trajectory.
What to watch
Monitor whether the revenue trend stabilizes or continues to decline in upcoming quarters.